ZA200708106B - Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity - Google Patents

Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Info

Publication number
ZA200708106B
ZA200708106B ZA200708106A ZA200708106A ZA200708106B ZA 200708106 B ZA200708106 B ZA 200708106B ZA 200708106 A ZA200708106 A ZA 200708106A ZA 200708106 A ZA200708106 A ZA 200708106A ZA 200708106 B ZA200708106 B ZA 200708106B
Authority
ZA
South Africa
Prior art keywords
synthesis
androgens
pharmacokinetics
novel
biological activities
Prior art date
Application number
ZA200708106A
Other languages
English (en)
Inventor
Brodie Angela
Njar Vincent
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of ZA200708106B publication Critical patent/ZA200708106B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200708106A 2005-03-02 2007-09-20 Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity ZA200708106B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02

Publications (1)

Publication Number Publication Date
ZA200708106B true ZA200708106B (en) 2008-12-31

Family

ID=36941503

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708106A ZA200708106B (en) 2005-03-02 2007-09-20 Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Country Status (22)

Country Link
US (1) US7875599B2 (ru)
EP (2) EP2206719B1 (ru)
JP (2) JP5130453B2 (ru)
KR (1) KR101380959B1 (ru)
CN (2) CN101155823A (ru)
AT (1) ATE482969T1 (ru)
AU (1) AU2006218711B2 (ru)
BR (1) BRPI0607523A2 (ru)
CA (1) CA2599953C (ru)
DE (1) DE602006017175D1 (ru)
DK (2) DK1853619T3 (ru)
EA (1) EA019560B1 (ru)
ES (2) ES2528055T3 (ru)
HK (1) HK1115387A1 (ru)
IL (3) IL185608A (ru)
MX (1) MX2007010593A (ru)
NZ (1) NZ561571A (ru)
PL (2) PL1853619T3 (ru)
PT (2) PT1853619E (ru)
SI (2) SI2206719T1 (ru)
WO (1) WO2006093993A1 (ru)
ZA (1) ZA200708106B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
SI2206719T1 (sl) 2005-03-02 2015-03-31 University Of Maryland, Baltimore Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien
CA2726734C (en) 2007-06-06 2014-10-07 University Of Maryland, Baltimore Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer
GB2470873A (en) * 2008-03-12 2010-12-08 Univ Maryland Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
US20100048524A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009120565A2 (en) * 2008-03-25 2009-10-01 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
WO2009129208A2 (en) * 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
US20110190323A1 (en) 2008-08-28 2011-08-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses thereof
CN102282133A (zh) * 2008-10-28 2011-12-14 生物马林药物股份有限公司 十氢-1h-茚并喹啉酮和十氢-3h-环戊并菲啶酮cyp17抑制剂
AU2010210422A1 (en) * 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
WO2010091303A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel steroidal cyp17 inhibitors/antiandrogens
GB2479337A (en) * 2009-02-05 2011-10-05 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
ES2475945T3 (es) 2009-06-26 2014-07-11 Novartis Ag Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
US8791094B2 (en) 2009-08-07 2014-07-29 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
WO2011059969A2 (en) * 2009-11-13 2011-05-19 Tokai Pharmaceuticals, Inc. Mammalian metabolites of steroids
EP2506855A4 (en) * 2009-11-30 2014-07-30 Harbor Biosciences Inc ANTICARCINOMA COMPOUNDS AND SCREENING METHODS
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
CA2819515A1 (en) * 2010-12-16 2012-06-21 Biomarin Pharmaceutical Inc. Cyp11b, cyp17, and/or cyp21 inhibitors
CA2834224A1 (en) 2011-04-28 2012-11-01 Novartis Ag 17.alpha.-hydroxylase/c17,20-lyase inhibitors
WO2013012959A1 (en) * 2011-07-18 2013-01-24 Tokai Pharmaceuticals, Inc. Novel compositions and methods for treating prostate cancer
US20150005265A1 (en) * 2011-12-22 2015-01-01 Susan Stewart Methods and compositions for combination therapy using p13k/mtor inhibitores
EP4066841A1 (en) 2013-03-14 2022-10-05 University of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
AU2014247941C1 (en) 2013-04-04 2019-10-31 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
SG11201600525XA (en) * 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3505521A1 (en) 2013-12-24 2019-07-03 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
CN105732759A (zh) * 2015-01-29 2016-07-06 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017066697A1 (en) 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
CH714173B1 (it) * 2016-08-08 2021-04-15 Ind Chimica Srl Processo per la preparazione di 3ß-idrossi-17-(1H-benzimidazol-1-il)androsta-5,16-diene.
US20200369715A1 (en) * 2018-02-13 2020-11-26 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
WO2019160890A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (ru) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
BRPI0412989A (pt) 2003-07-29 2006-10-03 Dompe Spa combinação farmacêutica útil para mobilização de célula-tronco
SI2206719T1 (sl) 2005-03-02 2015-03-31 University Of Maryland, Baltimore Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien

Also Published As

Publication number Publication date
BRPI0607523A2 (pt) 2009-09-08
ES2353413T3 (es) 2011-03-01
KR20070120119A (ko) 2007-12-21
IL210478A0 (en) 2011-03-31
PT1853619E (pt) 2011-01-03
AU2006218711B2 (en) 2010-11-11
PL2206719T3 (pl) 2015-03-31
IL185608A (en) 2016-06-30
EA200701872A1 (ru) 2008-06-30
ES2528055T3 (es) 2015-02-03
DK2206719T3 (en) 2015-01-26
PT2206719E (pt) 2015-02-05
HK1115387A1 (ru) 2008-11-28
ATE482969T1 (de) 2010-10-15
EP1853619A4 (en) 2009-08-26
AU2006218711A2 (en) 2006-09-08
CA2599953A1 (en) 2006-09-08
CN101155823A (zh) 2008-04-02
EA019560B1 (ru) 2014-04-30
IL185608A0 (en) 2008-01-06
JP2012255026A (ja) 2012-12-27
US20080280864A1 (en) 2008-11-13
IL210480A0 (en) 2011-03-31
MX2007010593A (es) 2008-02-20
EP2206719B1 (en) 2014-10-22
IL210480A (en) 2015-06-30
EP2206719A2 (en) 2010-07-14
DE602006017175D1 (de) 2010-11-11
EP2206719A3 (en) 2011-01-05
CA2599953C (en) 2013-08-13
DK1853619T3 (da) 2011-01-10
EP1853619B1 (en) 2010-09-29
US7875599B2 (en) 2011-01-25
KR101380959B1 (ko) 2014-04-04
JP2008536807A (ja) 2008-09-11
NZ561571A (en) 2009-09-25
PL1853619T3 (pl) 2011-03-31
SI1853619T1 (sl) 2011-01-31
WO2006093993A1 (en) 2006-09-08
EP1853619A1 (en) 2007-11-14
JP5613206B2 (ja) 2014-10-22
JP5130453B2 (ja) 2013-01-30
SI2206719T1 (sl) 2015-03-31
CN103349664A (zh) 2013-10-16
AU2006218711A1 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
ZA200708106B (en) Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
GB2470700A (en) Novel prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogans: synthesis, in vitro biological activities, Pharmacokinetics and antitumor activity
AU2010210422A8 (en) Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
WO2006044379A3 (en) Novel curcumin analogues and uses thereof
HRP20150437T1 (en) Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
HK1061354A1 (en) Synthesis of 4-amino-thalidomide enantiomers
WO2003088927A3 (en) Novel curcumin analogues and uses thereof
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
PT1928882E (pt) (s)-n-metilnaltrexona, processo para a sua síntese e sua utilização farmacêutica
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2006052889A3 (en) Quinolinone-carboxamide compounds
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
TW200612925A (en) Prodrug substituted benzoxazoles as estrogenic agents
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
GB2453402A (en) Bis-pyyrolo[2.1.-c] benzodiazepine-anthraquinone conjugates as antitumour agents and a process for the preparation thereof
WO2008057604A3 (en) Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
WO2006034478A3 (en) Isomigrastatin analogs in the treatment of cancer
WO2008073752A3 (en) Cyclobutyl derivatives for the treatment of glaucoma
CY1115910T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE
TW200603812A (en) D-homo-17-chlor-16(17)-ene steroids